Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)
Launched by ANDREAS MONSCH · Aug 8, 2017
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
The Montreal Cognitive Assessment (MoCA) is a short tool to evaluate a multitude of cognitive domains (visuospatial / executive functioning, object naming, memory, attention, language, abstraction, orientation). The original English MoCA consistently showed very high sensitivity and specificity in distinguishing patients with mild cognitive impairment from healthy controls. Therefore it is an excellent tool for early recognition of cognitive disorders. Based on a Canadian sample, the MoCA proposes a cut-off-value of 26/30 points. However, there is increasing evidence of intercultural differ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥65 years
- • Education ≥7 years
- • Fluency in the German language
- • Written informed consent
- Exclusion Criteria:
- • History of cognitive impairment
- • Depression
- • Severe sensory or motor impairment interfering with cognitive testing
- • Serious somatic disease
- • Disease or event affecting the central nervous system
- • Cerebrovascular disease
- • Regular medication with psychoactive drugs except for benzodiazepines
- • Participation in a cognitive study within the last 3 months
About Andreas Monsch
Andreas Monsch is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a focus on delivering high-quality, ethically conducted clinical studies, Monsch aims to facilitate the development of new therapies and treatment options that improve patient outcomes. Leveraging a robust network of collaborators and a wealth of expertise in trial design and execution, the organization prioritizes patient safety and regulatory compliance while fostering transparency and integrity throughout the research process. Through its initiatives, Andreas Monsch strives to contribute significantly to the scientific community and enhance the landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alessandra Thomann, MSc
Principal Investigator
Felix Platter Hospital Basel
Nicolai Goettel, MD
Principal Investigator
University Hospital, Basel, Switzerland
Raphael Monsch, MD
Principal Investigator
University Hospital, Basel, Switzerland
Manfred Berres, PhD
Principal Investigator
University of Applied Sciences Koblenz
Andreas Monsch, PhD
Study Chair
Felix Platter Hospital Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials